European Commission - Press release
Mergers: Commission approves acquisition of Swiss pharma company Nycomed by Takeda of Japan
Brussels, 02 August 2011 - The European Commission has cleared under the EU Merger Regulation the acquisition of pharmaceutical company Nycomed of Switzerland by rival Takeda of Japan. Both Takeda and Nycomed supply proton pump inhibitors (PPIs), a type of drug used to treat a range of common disorders related to acid secretion by the stomach.
The Commission's examination of the proposed transaction showed that the combined market share of Takeda and Nycomed in Austria, Germany and Italy, where they both sell the product concerned, is not very high and they will face the competitive constraint exerted by other companies in the sector.
As a result, the Commission concluded that the transaction would not significantly impede effective competition in the European Economic Area (EEA) or any substantial part of it.
Takeda is a Japanese global group of companies whose activities are divided into three business segments: ethical (or prescription) drugs, consumer healthcare and other businesses (including the manufacture and marketing of reagents, clinical diagnostics and chemical products). Nycomed of Switzerland offers a diversified product range focused on branded prescription medicines, consumer healthcare products and a contract manufacturing business.
The transaction was notified to the Commission on 26 June 2011.
Merger control rules and procedures
The Commission, in 1989, was given the power to assess mergers and acquisitions involving companies with a turnover above certain thresholds (see Article 1 of the Merger Regulation). Its duty is to prevent concentrations that would significantly impede effective competition in the European Economic Area (EEA)1 or any substantial part of it.
The vast majority of mergers do not pose competition problems and are cleared after a routine review. From the moment a transaction is notified, the Commission generally has a total of 25 working days to decide whether to grant approval (Phase I) or to start an in-depth investigation (Phase II).
A non-confidential version of the decision will be available at:
The EU plus Norway, Iceland and Liechtenstein